Saturday, October 25, 2025

Latest

Pharmather Applies For Orphan Drug Status For Ketamine In Use Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) has filed for orphan drug designation with the US Food and Drug Administration for the use of ketamine in the treatment of levodopa-induced dyskinesia associated with Parkinson’s Disease. The filing was announced this morning by the firm.

The filing, if approved, would grant the company special status, enabling the accelerated development of ketamine to treat levodopa-induced dyskinesia associated with Parkinson’s (LID-PD). The orphan drug designation enables certain benefits and incentives to be available to the filer, which notably includes potential tax credits, eligibility for orphan drug grants, seven years of marketing exclusivity, and finally the waiver of certain admin fees.

The global Parkinson’s market, as per Pharmather, is expected to grow to US$7.5 billion by the end of 2025. It’s estimated that as a result, the target market for LID-PD within the US will be over roughly $3 billion as a result. Overall this represents significant growth for the market, given that it was $5 billion in size in 2019.

“The FDA ODD application leverages established clinical research and intellectual property that we have exclusively secured for ketamine in LID-PD and it complements our strategy in pursuing an FDA investigational new drug application to conduct a Phase 2 clinical study in LID-PD later this year.”

Fabio Chianelli, CEO

Notably, Ketamine is an FDA approved drug and is viewed as having a known safety profile as a result. Prior clinical reports conducted on the drug have provided the suggestion that in low doses, an infusion of ketamine is well tolerated by the body and can be used to improve pain and depression. Both of these clinical conditions are often comorbidities of Parkinson’s disease.

Pharmather Inc last traded at $0.20 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

When 4% of Global Copper Disappears Overnight | David Gower – Emerita Resources

Mining M&A: Gold X2 Acquires Kesselrun Resources

They Said Oil Was Dead. They Were Wrong. | Michael Judson – Record Resources

Recommended

Steadright Enters MOU To Acquire Historic Goundafa Polymetallic Mine In Morocco

Military Seizes Power in Madagascar After President Flees

Related News

PharmaTher Secures Japanese Patent For Ketabet

PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its...

Tuesday, November 30, 2021, 09:52:00 AM

Pharmather Files For Orphan Drug Status For Use Of Ketamine Against Postherpetic Neuralgia

Pharmather Inc (CSE: PHRM) this morning announced that it has filed for orphan drug status...

Tuesday, October 27, 2020, 08:42:25 AM

PharmaTher Sponsors Research For Novel Delivery Of Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that it has entered into a sponsored research...

Wednesday, March 24, 2021, 07:19:06 AM

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development...

Tuesday, January 19, 2021, 09:24:20 AM

PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target

PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th....

Wednesday, June 30, 2021, 02:38:00 PM